Original language | English (US) |
---|---|
Pages (from-to) | 1007-1008 |
Number of pages | 2 |
Journal | Cephalalgia |
Volume | 38 |
Issue number | 5 |
DOIs | |
State | Published - Apr 1 2018 |
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Re : Placebo responses in device studies. / Goadsby, Peter J.; Dodick, David W.; Lipton, Richard B.
In: Cephalalgia, Vol. 38, No. 5, 01.04.2018, p. 1007-1008.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Re
T2 - Placebo responses in device studies
AU - Goadsby, Peter J.
AU - Dodick, David W.
AU - Lipton, Richard B.
N1 - Funding Information: Dr Lipton He receives research support from the NIH: 2PO1 AG003949 (Program Director), 5U10 NS077308 (PI), 1RO1 AG042595 (Investigator), RO1 NS082432 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology and as senior advisor to Headache. He has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Colucid, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKlein, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff’s Headache, 8th Edition, Oxford Press University, 2009, Wiley and Informa. Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Goadsby reports, unrelated to this note, grants and personal fees from Allergan, Amgen, and Eli-Lilly and Company; and personal fees from Akita Biomedical, Alder Biopharmaceuticals, Avanir Pharma, Cipla Ltd, Dr Reddy’s Laboratories, eNeura, Electrocore LLC, Novartis, Pfizer Inc, Quest Diagnostics, Scion, Teva Pharmaceuticals, Trigemina Inc., Scion; and personal fees from MedicoLegal work, Journal Watch, Up-to-Date, Massachusetts Medical Society, Oxford University Press; and in addition, has a patent Magnetic stimulation for headache assigned to eNeura.
PY - 2018/4/1
Y1 - 2018/4/1
UR - http://www.scopus.com/inward/record.url?scp=85045302066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045302066&partnerID=8YFLogxK
U2 - 10.1177/0333102417722498
DO - 10.1177/0333102417722498
M3 - Letter
C2 - 28747062
AN - SCOPUS:85045302066
VL - 38
SP - 1007
EP - 1008
JO - Cephalalgia
JF - Cephalalgia
SN - 0333-1024
IS - 5
ER -